These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

102 related articles for article (PubMed ID: 27295707)

  • 21. [The new insulins].
    Krzentowski G
    Rev Med Brux; 2005 Sep; 26(4):S241-5. PubMed ID: 16240869
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Use of rapid-acting insulin analogues in the treatment of patients with type 1 and type 2 diabetes mellitus: insulin pump therapy versus multiple daily injections.
    Bode BW
    Clin Ther; 2007; 29 Suppl D():S135-44. PubMed ID: 18191065
    [TBL] [Abstract][Full Text] [Related]  

  • 23. An analysis of the cost-effectiveness of switching from biphasic human insulin 30, insulin glargine, or neutral protamine Hagedorn to biphasic insulin aspart 30 in people with type 2 diabetes.
    Gupta V; Baabbad R; Hammerby E; Nikolajsen A; Shafie AA
    J Med Econ; 2015 Apr; 18(4):263-72. PubMed ID: 25426701
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Biphasic insulin aspart in the treatment of type 2 diabetes mellitus.
    Cucinotta D; Russo GT
    Expert Opin Pharmacother; 2009 Dec; 10(17):2905-11. PubMed ID: 19929709
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Efficacy and safety of the second generation basal insulin analogs in type 2 diabetes mellitus: A critical appraisal.
    Hernando VU; Pablo FJ
    Diabetes Metab Syndr; 2019; 13(3):2126-2141. PubMed ID: 31235147
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Basal insulins: Pharmacological properties and patient perspectives.
    Abrahamson MJ
    Prim Care Diabetes; 2010 Apr; 4 Suppl 1():S19-23. PubMed ID: 20394887
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Safety of once-daily insulin detemir in patients with type 2 diabetes treated with oral hypoglycemic agents in routine clinical practice.
    Ross S; Dzida G; Ji Q; Kaiser M; Ligthelm R; Meneghini L; Nazeri A; Orozco-Beltran D; Pan C; Svendsen AL;
    J Diabetes; 2014 May; 6(3):243-50. PubMed ID: 24103141
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Reducing hypoglycaemia with insulin analogues.
    Heller S
    Int J Obes Relat Metab Disord; 2002 Sep; 26 Suppl 3():S31-6. PubMed ID: 12174321
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Similar glucose control with basal-bolus regimen of insulin detemir plus insulin aspart and thrice-daily biphasic insulin aspart 30 in insulin-naive patients with type 2 diabetes: Results of a 50-week randomized clinical trial of stepwise insulin intensification.
    Malek R; Ajili F; Assaad-Khalil SH; Shinde A; Chen JW; Van den Berg E
    Diabetes Metab; 2015 Jun; 41(3):223-30. PubMed ID: 25483023
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Safety of insulin analogues as compared with human insulin in pregnancy.
    Toledano Y; Hadar E; Hod M
    Expert Opin Drug Saf; 2016 Jul; 15(7):963-73. PubMed ID: 27145344
    [TBL] [Abstract][Full Text] [Related]  

  • 31. The development of new basal insulins: is there any clinical advantage with their use in type 2 diabetes?
    Maiorino MI; Petrizzo M; Capuano A; Giugliano D; Esposito K
    Expert Opin Biol Ther; 2014 Jun; 14(6):799-808. PubMed ID: 24673155
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Comment on Khunti et al. Hypoglycemia and risk of cardiovascular disease and all-cause mortality in insulin-treated people with type 1 and type 2 diabetes: a cohort study. Diabetes care 2015;38:316-322.
    Giménez M; Amor AJ; Quirós C; Conget I
    Diabetes Care; 2015 Jun; 38(6):e91. PubMed ID: 25998305
    [No Abstract]   [Full Text] [Related]  

  • 33. New Horizons: Next-Generation Insulin Analogues: Structural Principles and Clinical Goals.
    Jarosinski MA; Chen YS; Varas N; Dhayalan B; Chatterjee D; Weiss MA
    J Clin Endocrinol Metab; 2022 Mar; 107(4):909-928. PubMed ID: 34850005
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Primary Care Management of Patients With Type 2 Diabetes: Overcoming Inertia and Advancing Therapy With the Use of Injectables.
    Santos Cavaiola T; Kiriakov Y; Reid T
    Clin Ther; 2019 Feb; 41(2):352-367. PubMed ID: 30655008
    [TBL] [Abstract][Full Text] [Related]  

  • 35. The Relevance of Clinical Pharmacology Studies of Basal Insulins to Primary Care.
    Reid TS; White J; Meneghini L
    J Fam Pract; 2019 Jan; 68(1 Suppl):. PubMed ID: 30677105
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Case study: lessons learned in the care of a 63-year-old woman with type 2 diabetes.
    Davidson JA
    Clin Cornerstone; 2005; 7 Suppl 3():S18-24. PubMed ID: 16545733
    [TBL] [Abstract][Full Text] [Related]  

  • 37. [Update on the use of insulins for the primary care physician].
    López-Simarro F; Cols-Sagarra C; Mediavilla Bravo JJ; Cañís-Olivé J; Hernández-Teixidó C; González Mohíno Loro MB
    Semergen; 2022; 48(1):54-62. PubMed ID: 34266759
    [TBL] [Abstract][Full Text] [Related]  

  • 38. New Insulins, Biosimilars, and Insulin Therapy.
    Danne T; Heinemann L; Bolinder J
    Diabetes Technol Ther; 2018 Feb; 20(S1):S55-S70. PubMed ID: 29437477
    [No Abstract]   [Full Text] [Related]  

  • 39. New perspectives on insulin therapy.
    Araki E; Araki H; Senokuchi T; Motoshima H
    J Diabetes Investig; 2020 Jul; 11(4):795-797. PubMed ID: 32232932
    [No Abstract]   [Full Text] [Related]  

  • 40. One hundred years of insulin therapy.
    Mathieu C; Martens PJ; Vangoitsenhoven R
    Nat Rev Endocrinol; 2021 Dec; 17(12):715-725. PubMed ID: 34404937
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 6.